冠心病PCI术后抗凝类药物使用情况及不良反应调查分析

Analysis of the Use of Anticoagulant Drugs and Adverse Reactions in Patients with Coronary Heart Disease After PCI

目的:探讨冠心病(CHD)经皮冠状动脉介入术(PCI)后凝类药物使用情况及不良反应。方法:收集2018年12月—2021年12月我院行PCI术的80例CHD患者一般资料,分析抗凝药品种类数、使用疗程、使用剂量以及不同年龄段患者PCI术后不良反应发生率。结果:80例CHD患者PCI术后使用抗凝药物,有11例患者出现了不良反应;联合应用抗凝药物≥5、抗凝药物使用疗程≥15 d、超剂量使用抗凝药物以及年龄≥75岁患者的不良反应发生率最高,依次为17.39%、23.07%、20.00%、33.33%。结论:CHD患者PCI术后联用多种抗凝药物、使用疗程较长且剂量较大会增加不良反应的发生风险,同时对于年龄较大的CHD患者应加强抗凝药物的安全用药管理。

Objective:To investigate the use and adverse reactions of coagulation drugs after percutaneous coronary intervention(PCI)in patients with coronary heart disease(CHD).Methods:The general data of 80 CHD patients who underwent PCI in our hospital from December 2018 to December 2021 were collected to analyze the types,course of treatment,dosage of anticoagulant drugs and the incidence of adverse reactions after PCI in patients of different ages.Results:Anticoagulants were used in 80 CHD patients after PCI,and 11 patients had adverse reactions.The incidence of adverse reactions in patients with combined application of anticoagulant drugs≥5,course of anticoagulant drugs≥15 d,overdose of anticoagulant drugs and age≥75 years was the highest,which was 17.39%,23.07%,20.00%and 33.33%,respectively.Conclusion:CHD patients after PCI combined with a variety of anticoagulant drugs,long course of treatment and large dose will increase the risk of adverse reactions.At the same time,for older CHD patients,the safety management of anticoagulant drugs should be strengthened.